Ermenegildo Zegna (NYSE:ZGN – Get Rating) and Silo Pharma (NASDAQ:SILO – Get Rating) are both small-cap retail/wholesale companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings for Ermenegildo Zegna and Silo Pharma, as reported by MarketBeat.com.

Ermenegildo Zegna currently has a consensus price target of $11.90, indicating a potential upside of 6.63%. Given Ermenegildo Zegna's higher probable upside, equities research analysts clearly believe Ermenegildo Zegna is more favorable than Silo Pharma.

Valuation and Earnings

Silo Pharma has lower revenue, but higher earnings than Ermenegildo Zegna.

Profitability

This table compares Ermenegildo Zegna and Silo Pharma's net margins, return on equity and return on assets.

Institutional and Insider Ownership

45.3% of Ermenegildo Zegna shares are owned by institutional investors. Comparatively, 11.6% of Silo Pharma shares are owned by institutional investors. 1.2% of Ermenegildo Zegna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ermenegildo Zegna beats Silo Pharma on 8 of the 10 factors compared between the two stocks.

About Ermenegildo Zegna

(Get Rating)

Ermenegildo Zegna N.V., together with its subsidiaries, designs, manufactures, markets, and distributes luxury menswear, footwear, leather goods, and other accessories under the Zegna and the Thom Browne brands. It provides luxury leisurewear for men; formal suits, tuxedos, shirts, blazers, formal overcoats, and accessories; leather accessories comprising shoes, bags, belts, and small leather accessories; and fragrances. The company also offers luxury womenswear and childrenswear under the Thom Browne brand, as well as provides eyewear, cufflinks and jewelry, watches, underwear, and beachwear manufactured by third parties under licenses. It serves customers through its retail stores and online channels in Europe, the Middle East, Africa, North America, Latin America, the Asia Pacific, and internationally. The company was founded in 1910 and is based in Trivero, Italy. Ermenegildo Zegna N.V. is a subsidiary of Monterubello Societa' Semplice.

About Silo Pharma

(Get Rating)

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. It is developing solutions to address various underserved conditions. The company seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders. The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.

Receive News & Ratings for Ermenegildo Zegna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ermenegildo Zegna and related companies with MarketBeat.com's FREE daily email newsletter.